Investors



Stock price graph

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO® , which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place. 

 

Contacts:

Investors

Bob De Vaere
Chief Financial Officer
Horizon Pharma, Inc.
520 Lake Cook Road, Suite 520
Deerfield, IL 60015
bd@horizonpharma.com

Media

BiotechComm
E. Blair Clark-Schoeb
(917) 432-9275
blair@biotechcomm.com

View all   RSSRecent Releases

Horizon Pharma Announces the Appointment of H. Thomas Watkins to Its Board of Directors

DEERFIELD, IL -- (Marketwired) -- 04/17/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of H. Thomas Watkins, former director, president and chief executive officer of Human Genome Sciences, to its board of directors. Additionally, Jean-François Formela, M.D. has resigned from the Horizon board of directors. "Tom brings valuable industry experience to our board as a highly regarded biotechnology leader," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "As we continue to grow our commercial business and buil...

Read more »

Horizon Pharma Announces Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Vidara Therapeutics International Ltd.

DEERFIELD, IL -- (Marketwired) -- 04/16/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. ("Vidara"). The waiting period was scheduled to expire on May 1, 2014. Completion of the transaction remains subject to approval by Horizon's stockholders and other customary closing conditions. Horizon and Vidara previously announced their entry into a definitive agree...

Read more »

Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets

DEERFIELD, IL -- (Marketwired) -- 04/10/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS®. "This patent allowance by the USPTO is another important milestone in achieving our goal of protecting the innovation and commercial potential of RAYOS," stated Timothy P. Walbert, chairman, president and chief exec...

Read more »

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DEERFIELD, IL -- (Marketwired) -- 03/27/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that on March 27, 2014 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 96,750 shares of common stock to 26 new employees. Each stock option has an exercise price per share equal to $15.08, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereaft...

Read more »

Horizon Pharma to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

DEERFIELD, IL -- (Marketwired) -- 03/25/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, its chairman, president and chief executive officer, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 3:30 p.m. Eastern Time in New York, NY. Mr. Walbert will provide an overview of Horizon and its corporate activities. The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available on Ho...

Read more »